Inhibition of N-Glycosylation towards Novel Anti-Cancer Chemotherapeutics (original) (raw)

Abstract

Cell surface polysaccharides play important roles in numerous biological processes in living organisms such as maintenance of outer membrane integrity, mediators of host-pathogen interactions, cell-cell-adhesion and recognition, protein folding, cell signaling, and trafficking of proteins translated within the rough endoplasmic reticulum (ER) to the Golgi. Furthermore, abnormal glycosylation of cell surface proteins takes place during which normal cells progress to a malignant neoplastic state [1]. Thus, the modification of cell surface glycosylation is a characteristic of many cancer cells [2-4]. Many of the recently developed tumor markers are carbohydrate antigens. Identification of cell type-specific or tissue-specific glycoconjugates (tumor markers) has lead to the discovery of new assay systems or diagnosis for certain cancers via immunodetection reagents [1]. On the other hand, anti-glycan antibodies have a limited application for cancer treatment, despite the fact that a great number of tumor-associated glycans have been identified with the help of modern glycomic approaches [6]. In the last two decades, a few monoclonal antibodies targeting ganglioside GD 2 or GD 3 and a cancer vaccine with N-glycolylated ganglioside GM 3 have been developed into clinical trials. As such, changes and diversification of the expression profile of cell surface glycans based on the underlying glycobiology have received much attention from the scientific community [1]. Two of the most abundant forms of glycosylation occurring on proteins destined to be secreted or membrane-bound proteins are N-linked (to Asp (N), N-glycosylation) and mucin-type O-linked (to Ser/Thr, Oglycosylation). O-Linked glycosylation is an evolutionarily conserved protein modification found across species such as mammals, worms, insects, protozoa, and certain types of fungi, whereas N-linked glycosylation occurs in eukaryotes and widely in archaea, but very rarely in bacteria. Recent studies of cancer immunotherapy are based on immunogenicity of truncated O-glycan chains (e.g. Tn, sTn, T, and sLe a/x). Despite the importance of N-linked glycans in transformation-associated glycosylation changes for normal cells to develop tumor cells, therapeutic antibodies against N-linked glycans have not yet been developed. It may largely be attributable to the lack of specificity of N-linked glycans between normal and malignant cells. Abnormal (increased) branching of N-linked glycans has been observed in certain solid cancer cells. Altered glycosylation of N-linked glycans in cancers is typically associated with upregulation of β1,6-N-acetylyglucosaminyltransferase-5 (GnT5), enhancing β1,6-branching. Although it is an extremely challenging subject to discover druglike glycosyltransferases to block the biosynthesis of specific branching processes in cancer cells, N-glycan biosynthesis can be terminated by inhibition of the first committed enzyme, dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) activity [7-11].

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (17)

  1. Sterner E, Flanagan N, Gildersleeve JC. Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database. ACS Chem. Biol. 2016; 11:1773-1783. [PubMed: 27220698]
  2. Jeanes A, Gottardi CJ, Yap AS. Cadherins and Cancer: How Does Cadherin Dysfunction Promote Tumor Progression? Oncogene. 2008; 27:6920-6929. [PubMed: 19029934]
  3. Vargas DA, Sun M, Sadykov K, Kukuruzinska MA, Zaman, Muhammad H. The Integrated Role of Wnt/β-Catenin, N-Glycosylation, and E-Cadherin-mediated Adhesion in Network Dynamics. PLoS Computational Biol. 2016; 12:e1005007.
  4. Liu G, Sengupta PK, Jamal B, Yang HY, Bouchie MP, Lindner V, Varelas X, Kukuruzinska MA. N- Glycosylation Induces the CTHRC1 Protein and Drives Oral Cancer Cell Migration. J. Biol. Chem. 2013; 288:20217-20227. [PubMed: 23703614]
  5. Jamal B, Sengupta PK, GAO Z, Nita-Lazar M, Amin B, Jalisi SH, Bouchie MP, Kukuruzinska MA. Aberrant Amplification of the Crosstalk between Canonical Wnt signaling and N-Glycosylation Gene DPAGT1 Promotes Oral Cancer. Oral Oncology. 2012; 48:523-529. [PubMed: 22341307]
  6. Vankemmelbeke M, Chua JX, Durrant LG. Cancer Cell Associated Glycans as Targets for Immunotherapy. Oncoimmunol. 2016; 5(1):e1061177.
  7. Sengupta PK, Bouchie MP, Kukuruzinska MA. N-Glycosylation Gene DPAGT1 Is a Target of the Wnt/β-Catenin signaling pathway. J. Biol. Chem. 2010; 285:31164-31173. [PubMed: 20693288]
  8. Huang SH, Wang DI, Zhang SH, Huang XI, Wang D, Ijaz M, Shi Y. Tunicamycin Potentiates Paclitaxel-induced Apoptosis through Inhibition of PI3K/AKT and MAPK Pathways in Breast Cancer. Cancer Chemother. Pharmacol. 2017; 4:685-696.
  9. Banerjee A, Martinez J, Longas M, Zhang ZH, Santiago J, Baksi K, Banerjee D. N- Acetylglucosaminyl 1-phosphate Transferase: An Excellent Target for Developing New Generation Breast Cancer Therapeutic. Advances Exper. Med. Biol. 2015; 842:355-374. [PubMed: 25408354]
  10. Nami B, Donmez H, Kocak N. Tunicamycin-induced Endoplasmic Reticulum Stress Reduces In Vitro Subpopulation and Invasion of CD44+/CD24-Phenotype Breast Cancer Stem. Cells. 2016; 7:419-426.
  11. Hou H, Sun H, Lu P, Ge CH, Zhang L, Li H, Zhao F, Tian HUA, Zhang LIN, Chen T, Yao M, Li J. Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma. Mol. Cancer Therapeutics. 2013; 12:2874-2884.
  12. Nita-Lazar M, Rebustini I, Walker J, Kukuruzinska MA. Hypoglycosylated E-Cadherin Promotes the Assembly of Tight Junctions through the Recruitment of PP2A to Adherens Junctions. Experimental Cell Res. 2010; 316:1871-1884.
  13. Nita-Lazar M, Noonan V, Rebustini I, Walker J, Menko AS, Kukuruzinska MA. Overexpression of DPAGT1 Leads to Aberrant N-Glycosylation of E-Cadherin and Cellular Discohesion in Oral Cancer. Cancer Res. 2009; 69:5673-5680. [PubMed: 19549906]
  14. Lim E, Jin H, Jeonghoon K, Young HO. Tunicamycin Promotes Apoptosis in Leukemia Cells through ROS Generation and Downregulation of Surviving Expression. Apoptosis. 2015; 8:1087- 1098.
  15. Mitachi K, Siricilla S, Yang D, Kong Y, Skorupinska-Tudek K, Swiezewska E, Franzblau SG, Kurosu M. Fluorescence-based Assay for Polyprenyl phosphate-GlcNAc-1-phosphate Transferase (WecA) and Identification of Novel Antimycobacterial WecA inhibitors. Anal. Biochem. 2016; 512:78-90. [PubMed: 27530653]
  16. Katsuhiko M, Yun HG, Kurosu SM, Eslamimehr S, Lemieux MR, Klaić L, Clemons WM, Kurosu M. Novel FR-900493 Analogs that Inhibit Outgrowth of Clostridium difficile Spores. ACS Omega. 2018 Accepted for publication.
  17. de-Freitas-Junior JCM, Bastos LG, Freire-Neto CA, Rocher BD, Eliana Abdelhay SFW, Morgado- Díaz JA. N-Glycan Biosynthesis Inhibitors Induce In Vitro Anticancer Activity in Colorectal Cancer Cells. J. Cellular Biochem. 2012; 113:2957-2966. [PubMed: 22552949]